Skip to main content

Table 2 Non- immediate AEs by treatment course (n = 4,112)

From: Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients

  Incidence1per course Delay of onset (days)2 Regression of AEs3
Nodule/induration 234 (5.7%) [5.0 %; 6.4 %] 55 [29 – 91] 62/62 (100%)
Inflammation 27 (0.7%) [0.4%; 1.0%] 21 [0 – 57] 19/19 (100%)
Granuloma 13 (0.3%) [0.2%; 0.5%] 101 [69 – 117] 6/13 (46%)
Decolouration 9 (0.2%) [0.1 %; 0.4%] 92 [11 – 138] 2/2 (100%)
Skin hypertrophy 6 (0.1%) [0.1%; 0.3%] 84 [40 – 93] 1/1 (100%)
Allergic reactions 3 (0.1%) [0.0%; 0.2%] 1 [0 – 94] 1/1 (100%)
Skin atrophy 2 (0.0%) [0.0%; 0.2%] 66 [13 – 119]4 -
  1. 1n (%) [CI 95% exact].
  2. 2Median [Q1 – Q3] (calculated on documented data).
  3. 3n (% calculated on documented data).
  4. 4Reported values for the 2 cases.
  5. A treatment course had a mean of 3.8 injections.